ATE503846T1 - Verfahren zur diagnose eines ovarialkarzinoms - Google Patents
Verfahren zur diagnose eines ovarialkarzinomsInfo
- Publication number
- ATE503846T1 ATE503846T1 AT06790705T AT06790705T ATE503846T1 AT E503846 T1 ATE503846 T1 AT E503846T1 AT 06790705 T AT06790705 T AT 06790705T AT 06790705 T AT06790705 T AT 06790705T AT E503846 T1 ATE503846 T1 AT E503846T1
- Authority
- AT
- Austria
- Prior art keywords
- subject
- diagnosis
- sample
- markers
- ovarial carcinoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71694105P | 2005-09-15 | 2005-09-15 | |
| PCT/CA2006/001536 WO2007030949A2 (en) | 2005-09-15 | 2006-09-15 | Methods of diagnosing ovarian cancer and kits therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE503846T1 true ATE503846T1 (de) | 2011-04-15 |
Family
ID=37865291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06790705T ATE503846T1 (de) | 2005-09-15 | 2006-09-15 | Verfahren zur diagnose eines ovarialkarzinoms |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7910318B2 (de) |
| EP (1) | EP1924710B1 (de) |
| AT (1) | ATE503846T1 (de) |
| CA (1) | CA2622332A1 (de) |
| DE (1) | DE602006021038D1 (de) |
| ES (1) | ES2363757T3 (de) |
| WO (1) | WO2007030949A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| EP2589668A1 (de) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| US8664358B2 (en) | 2007-06-29 | 2014-03-04 | Vermillion, Inc. | Predictive markers for ovarian cancer |
| US20090088400A1 (en) * | 2007-09-11 | 2009-04-02 | Puymirat Jack | Prostaglandin e2 modulation and uses thereof |
| EP2281200A4 (de) * | 2008-04-23 | 2011-07-06 | Healthlinx Ltd | Testverfahren zum nachweis eines gynäkologischen leidens |
| HUE031848T2 (en) | 2008-09-20 | 2017-08-28 | Univ Leland Stanford Junior | Non-invasive diagnosis of fetal aneuploidy by sequencing |
| US8211659B2 (en) * | 2008-11-07 | 2012-07-03 | Tungs' Taichung Metroharbor Hospital | Methods and kits for detection of cancer metastasis |
| US20110201008A1 (en) * | 2009-12-01 | 2011-08-18 | University Of Miami | Assays, methods and kits for measuring response to therapy and predicting clinical outcome in patients with b-cell lymphoma |
| US20130224772A1 (en) * | 2010-08-26 | 2013-08-29 | University Of Washington Through Its Center For Commercialization | Method for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
| CN115925928A (zh) | 2013-09-05 | 2023-04-07 | Ab2生物股份有限公司 | 炎性疾病中的il-18结合蛋白(il-18bp) |
| US10882905B2 (en) | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010121A1 (en) * | 2001-03-16 | 2004-01-15 | Birse Charles E. | 7 Human ovarian and ovarian cancer associated proteins |
| US7189507B2 (en) * | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| AU2003235749A1 (en) | 2002-01-07 | 2003-07-24 | John Hopkins University | Biomarkers for detecting ovarian cancer |
| NZ562192A (en) * | 2002-08-06 | 2009-07-31 | Ciphergen Biosystems Inc | Use of biomarkers for detecting ovarian cancer |
| AU2004264948A1 (en) | 2003-08-15 | 2005-02-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Multifactorial assay for cancer detection |
| US7666583B2 (en) | 2004-02-19 | 2010-02-23 | Yale University | Identification of cancer protein biomarkers using proteomic techniques |
-
2006
- 2006-09-15 DE DE602006021038T patent/DE602006021038D1/de active Active
- 2006-09-15 AT AT06790705T patent/ATE503846T1/de not_active IP Right Cessation
- 2006-09-15 CA CA002622332A patent/CA2622332A1/en not_active Abandoned
- 2006-09-15 WO PCT/CA2006/001536 patent/WO2007030949A2/en not_active Ceased
- 2006-09-15 US US12/066,564 patent/US7910318B2/en not_active Expired - Fee Related
- 2006-09-15 ES ES06790705T patent/ES2363757T3/es active Active
- 2006-09-15 EP EP06790705A patent/EP1924710B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP1924710A2 (de) | 2008-05-28 |
| DE602006021038D1 (de) | 2011-05-12 |
| WO2007030949A2 (en) | 2007-03-22 |
| EP1924710A4 (de) | 2008-10-29 |
| US20080248501A1 (en) | 2008-10-09 |
| EP1924710B1 (de) | 2011-03-30 |
| US7910318B2 (en) | 2011-03-22 |
| WO2007030949A3 (en) | 2007-05-03 |
| CA2622332A1 (en) | 2007-03-22 |
| ES2363757T3 (es) | 2011-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE503846T1 (de) | Verfahren zur diagnose eines ovarialkarzinoms | |
| ATE471512T1 (de) | Verwendung des proteins s100a 12 als marker für kolorektalkarzinom | |
| WO2008021290A8 (en) | Organ-specific proteins and methods of their use | |
| ATE408828T1 (de) | Verfahren zur erkennung eines ovarialkarzinoms | |
| DE60300339D1 (de) | Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben | |
| ATE365922T1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
| CA2701341A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| JP2009537798A5 (de) | ||
| KR100711046B1 (ko) | 대장암에 대한 마커로서의 니코틴아미드n―메틸트랜스퍼라아제의 용도 | |
| DE602007007775D1 (de) | Reagenz für hämoglobinabbau | |
| TW200745551A (en) | Device and methods for detecting and quantifying one or more target agents | |
| ATE529533T1 (de) | Verfahren zum nachweis von analyten in einer probe | |
| FI20040255A7 (fi) | Menetelmä pre-eklampsian riskin havaitsemiseksi | |
| ATE514948T1 (de) | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen | |
| ATE462803T1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
| ATE534037T1 (de) | Verwendung des proteins asc als marker für brustkrebs | |
| ATE353544T1 (de) | Verwendung des proteins masp als marker für kolorektale karzinome | |
| WO2011032584A3 (en) | Method for sample identification in a mammal as well as a kit for performing this method | |
| EP1767652A4 (de) | Genmarker und dessen verwendung | |
| ATE472611T1 (de) | Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression | |
| ATE394675T1 (de) | Verfahren zum nachweis von brustkrebs | |
| DE602005014659D1 (de) | Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs | |
| ATE466285T1 (de) | Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers | |
| ATE393393T1 (de) | Verwendung des proteins spee als marker für brustkrebs | |
| ATE509270T1 (de) | Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |